Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | PGR | P06401 | 3/20 | 0.57 |
| ▸ | AR | P10275 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | SHBG | P04278 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17419486 | 0.99 | LMNA (0.74) | LMNAMAPTCYP3A4PGRAR | |
| SCHEMBL21067996 | 0.91 | MAPT (0.84) | LMNAMAPTCYP3A4PGRAR | |
| Cyclohexane SCHEMBL8027519 | 0.88 | MAPT (0.76) | LMNAMAPTCYP3A4PGRAR | |
| SCHEMBL23752494 | 0.87 | MAPT (0.78) | LMNAMAPTCYP3A4PGRAR | |
| SCHEMBL17419472 | 0.87 | MAPT (0.78) | LMNAMAPTCYP3A4PGRAR | |
| SCHEMBL11854733 | 0.86 | LMNA (0.59) | LMNAMAPTCYP3A4PGRAR | |
| SCHEMBL343128 | 0.86 | MAPT (0.79) | LMNAMAPTCYP3A4PGRAR | |
| SCHEMBL17419490 | 0.85 | MAPT (0.98) | LMNAMAPTCYP3A4PGRAR | |
| SCHEMBL11121455 | 0.85 | MAPT (0.75) | LMNAMAPTCYP3A4PGRAR | |
| SCHEMBL5155074 | 0.85 | LMNA (0.55) | LMNAMAPTCYP3A4PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 604 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616072-B2 | Reduction of side effects from aromatase inhibitors used for treating breast cancer | CHAVAH PTY LTD. (AU) | 2017-04-11 | — | — | US | claimed |
| US-20160129015-A1 | Reduction of Side Effects from Aromatase Inhibitors Used for Treating Breast Cancer | Havah Therapeutics Pty Ltd. (AU) | 2016-05-12 | — | — | US | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20120122824-A1 | Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer | CHAVAH PTY LTD (AU) | 2012-05-17 | — | — | US | claimed |
| EP-1945224-B1 | REDUCTION OF SIDE EFFECTS FROM AROMATASE INHIBITORS USED FOR TREATING BREAST CANCER | CHAVAH PTY LTD (AU) | 2012-05-02 | — | — | EP | claimed |
| US-20110195114-A1 | TRANSDERMAL DELIVERY SYSTEMS FOR ACTIVE AGENTS | ANTARES PHARMA, IPL, AG | 2011-08-11 | — | — | US | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| US-20100112027-A1 | Penis Enlargement | ADAMS KENNETH W | 2010-05-06 | — | — | US | claimed |
| US-20090215731-A1 | Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer | CHAVAH PTY LTD. (AU) | 2009-08-27 | — | — | US | claimed |
| WO-2002051420-A2 | METHODS AND FORMULATIONS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | ENDEAVOR PHARMACEUTICALS (US) | 2002-07-04 | — | — | WO | claimed |
| EP-1150629-A1 | DRUG DOSAGE UNIT FOR BUCCAL ADMINISTRATION OF STEROIDAL ACTIVE AGENTS | Place, Virgil A. (US) | 2001-11-07 | — | — | EP | claimed |
| US-20010036483-A1 | Transdermal administration of androgenic drugs using hydroxide-releasing agents as permeation enhancers | TECHNOLOGY RECOVERY SYSTEMS, LLC | 2001-11-01 | — | — | US | claimed |
| US-6284263-B1 | Buccal drug administration in the treatment of female sexual dysfunction | PLACE VIRGIL A (US) | 2001-09-04 | — | — | US | claimed |
| US-6241529-B1 | AFFIXING DOSAGE UNIT COMPRISED OF A COMPRESSED TABLET OF A BIOERODIBLE POLYMERIC CARRIER AND ANDROGENIC AGENT, PROGESTIN, AND ESTROGEN TO BUCCAL MUCOSA; USEFUL FOR FEMALE HORMONE REPLACEMENT THERAPY, CONTRACEPTION, AND SEXUAL DYSFUNCTION | Place, Virgil A. | 2001-06-05 | — | — | US | claimed |
| US-6221379-B1 | BUCCAL DOSAGE UNIT COMPRISED OF A COMPRESSED TABLET OF A BIOERODIBLE POLYMERIC CARRIER AND AN ANDROGENIC AGENT; A PROGESTIN AND AN ESTROGEN; AND AFFIXING THE DOSAGE UNIT TO THE BUCCAL MUCOSA OF THE INDIVIDUAL | Place, Virgil A. | 2001-04-24 | — | — | US | claimed |
| US-6180682-B1 | COMPRESSION TABLET IN POLYMERIC CARRIER | Place, Virgil A. | 2001-01-30 | — | — | US | claimed |
| US-6117446-A | A BUCCAL DOSAGE UNIT FOR ADMINISTERING A COMBINATION OF STEROIDAL ACTIVE AGENTS, COMPRISING A COMPRESSED TABLET OF A BIOERODIBLE POLYMERIC CARRIER AND AN ANDROGENIC AGENT SELECTED FROM TESTOSTERONE AND ESTERS, PROGESTIN AND ESTEROGEN | PLACE, VIRGIL A. | 2000-09-12 | — | — | US | claimed |
| WO-2000042955-A1 | DRUG DOSAGE UNIT FOR BUCCAL ADMINISTRATION OF STEROIDAL ACTIVE AGENTS | PLACE VIRGIL A (US) | 2000-07-27 | — | — | WO | claimed |
| WO-2000042942-A2 | BUCCAL DRUG DELIVERY SYSTEM FOR USE IN MALE CONTRACEPTION | PLACE VIRGIL A (US) | 2000-07-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | LMNA 1578/4885MAPT 3020/4885CYP3A4 867/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | LMNA 1578/4885MAPT 3020/4885CYP3A4 867/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | LMNA 1578/4885MAPT 3020/4885CYP3A4 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.